ArticleJournal of nanobiotechnology2025
Oral administration of Momordica charantia-derived extracellular vesicles alleviates ulcerative colitis through comprehensive renovation of the intestinal microenvironment.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Advances of oral micro- and nanomedicines for modulating intestinal barriers in the treatment of intestinal diseases.Acta pharmaceutica Sinica. B · 2026Review
- Past, Present, and Future of Plant-Derived Extracellular Vesicles in Biomedical Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Extremophyte-derived exosome-like nanovesicles remodel intestinal barrier dysfunction by multi-dimensional intervention: physical barrier repair with immune homeostasis and microbiome regulation.Journal of nanobiotechnology · 2026Article
- Review
- Mitochondrial Dysfunction in Ulcerative Colitis: Pathogenic Mechanisms and Novel Therapeutics.Journal of biochemical and molecular toxicology · 2026Review
- Medicinal Plant-Derived Exosome-like Nanoparticles: From Basic Research to Biomedical Applications.Pharmaceutics · 2026Review
- Plant-Derived Nanovesicles: A Comprehensive Review from Isolation to Clinical Translation-Unlocking Natural Nanocarriers for Biomedical Applications.Biomolecules · 2026Review
- Pomegranate peel-derived exosome-like nanoparticles: A discarded treasure trove for colorectal cancer treatment.Oncology letters · 2026Article
- Biogenesis, preparation, characterization, therapeutic mechanisms and safety evaluation of plant-derived exosome-like nanovesicles in the treatment of ulcerative colitis.Journal of nanobiotechnology · 2026Review
- Purification and Anti-Inflammatory Activity of Walnut Exosome-like Nanoparticles.Foods (Basel, Switzerland) · 2026Article
- Ginsenoside Rg1 promotes skin flap survival by alleviating mitochondrial oxidative stress and apoptosis via the JNK/ERK/p38 pathway.Journal of ginseng research · 2026Article
- Engineered chitosan/HP-β-CD hydrogel for targeted co-delivery of curcumin and berberine for the treatment of ulcerative colitis.Journal of biological engineering · 2026Article
- Bioengineered probiotics derived bacterial extracellular vesicle as bioactive nanocarrier for the local VEGF expression to accelerate wound healing.Journal of nanobiotechnology · 2026Article
- Oral plant-derived exosome-like nanovesicles: a new therapeutic perspective for intestinal diseases.Frontiers in pharmacology · 2026Review
- Plant-Derived Exosomes in Aesthetic Medicine.Biomaterials research · 2026Review
- Microbial metabolic memory in inflammatory bowel disease: microbiota-derived metabolites, host-microbe reprogramming, and relapse susceptibility.Frontiers in microbiology · 2026Review
- Extracellular vesicle-based therapies in IBD: immunomodulation, regeneration, and translation.Frontiers in immunology · 2026Review
- Harnessing plant-derived extracellular vesicles in advanced biomaterials: from structural scaffolds to responsive systems for next-generation wound therapeutics.Burns & trauma · 2026Review
- Plant-Derived Nanovesicles for Ischemic Stroke Therapy via the Gut Microbiota-Gut-Brain Axis: A New Paradigm of Systemic Regulation.International journal of nanomedicine · 2026Review
- Plant-derived extracellular vesicles as emerging biotherapeutic agents and delivery vehicles for rheumatoid arthritis: evidence from preclinical models.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is an inflammatory bowel disease (IBD), accompanied by intense inflammation, oxidative stress, and intestinal microbiota dysbiosis. Current treatments using chemotherapeutic drugs or immunosuppressants have limited effectiveness and side effects. Therefore, the development of safe, effective, and multi-targeting therapies for IBD is of great importance. Momordica charantia exhibits antioxidant, anti-inflammatory, and intestinal microbiota-regulating properties, suggesting that Momordica charantia-derived extracellular vesicles (MCEVs) have the potential for UC management.
resultsWe extracted MCEVs using differential centrifugation and density gradient centrifugation. The results showed that MCEVs possessed high purity, even particle size, and excellent stability. In vitro, MCEVs were shown to inhibit macrophage inflammatory responses, scavenge reactive oxygen species (ROS), and protect cells from oxidative damage. Transcriptomics analysis revealed that MCEVs may alleviate mitochondria-dependent apoptosis by safeguarding the integrity of the mitochondrial structure and regulating the expression of apoptosis-related proteins. Furthermore, all components of MCEVs contributed to their pharmacological activity. In vivo, MCEVs had better retention in the inflamed colon and significantly alleviated UC through a comprehensive renovation of the intestinal microenvironment.
conclusionThese findings suggested that MCEVs own considerable potential as natural nanotherapeutics for UC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.